Live Breaking News & Updates on Division Of Hematology At Yale Cancer Center

Stay updated with breaking news from Division of hematology at yale cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial. ....

United States , New Haven , Samer Zeidan , Hematology Early Therapeutics Research , Division Of Hematology At Yale Cancer Center , Disease Aligned Research Team , World Health Organization , Continuing Medical Education , Yale Cancer Center ,

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial. ....

New Haven , United States , Samer Zeidan , Division Of Hematology At Yale Cancer Center , Disease Aligned Research Team , World Health Organization , Hematology Early Therapeutics Research , Continuing Medical Education , Yale Cancer Center , 2023 Asco Annual Meeting , Asco Annual Meeting , Ct02598661 , Phase 3 Imerge Trial , Myelodysplastic Syndrome ,